New Trends in Financing Biotechnology

Patterns of biotechnology financing have undergone subtle shifts in recent months, and the shifts are an indication that the industry is moving from childhood into adolescence. Once the central source of support for U.S. biotechnology, venture capital has become somewhat less important, while tax-saving R&D limited partnerships are on the rise, and the trickle of public stock offerings has become a torrent. Around the world, but especially in Europe, governments are encouraging indigenous efforts in biotechnology. Many are backing up their encouragement with cash.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Author information

  1. This article is based on contributions by Vivian Lee, John Gurnsey, and Arthur Klausner, with additional material supplied by Ross Butler, Patricia Ann Duncan, Don Herichsen, Laura Mazur, Michael Stone, and Anne Zotov. It was edited by Tabitha M. Powledge.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Lee, V., Gurnsey, J. & Klausner, A. New Trends in Financing Biotechnology. Nat Biotechnol 1, 544–559 (1983).

    Download citation